Advertisement
Screener

Novartis AG (NVS) Graph

NVS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2025-06-30: Research and development $2.73B; Selling, general and administrative $3.44B.
  • 2024-06-30: Research and development $2.37B; Selling, general and administrative $3.09B.
  • 2023-06-30: Research and development $2.30B; Selling, general and administrative $3.09B.
  • 2022-06-30: Research and development $2.50B; Selling, general and administrative $3.58B.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentSelling, general and administrative
2025-06-30$2.73B$3.44B
2024-06-30$2.37B$3.09B
2023-06-30$2.30B$3.09B
2022-06-30$2.50B$3.58B
2021-06-30$2.40B$3.75B
2020-06-30$2.44B$3.37B
2019-06-30$2.05B$3.58B
2018-06-30$2.13B$3.50B
2017-06-30$2.06B$3.81B

Revenue and expense 6 month

Period endResearch and developmentSelling, general and administrative
2025-06-30$5.09B$6.50B
2024-06-30$4.79B$5.93B
2023-06-30$4.88B$5.98B
2022-06-30$4.82B$7.09B
2021-06-30$4.75B$7.28B
2020-06-30$4.50B$6.85B
2019-06-30$4.35B$6.92B
2018-06-30$4.11B$6.78B
2017-06-30$4.23B$7.28B

Revenue and expense 12 month

Period endResearch and developmentSelling, general and administrative
2025-12-31$11.20B$13.25B
2024-12-31$10.02B$12.57B
2023-12-31$11.37B$12.52B
2022-12-31$9.17B$12.19B
2021-12-31$8.64B$12.83B
2020-12-31$8.98B$14.20B
2019-12-31$9.40B$14.37B
2018-12-31$8.49B$13.72B
2017-12-31$8.39B$12.46B
2016-12-31$9.04B$14.19B
2015-12-31$8.94B(m)